On July 6, Johnson & Johnson will host an exclusive scientific symposium, showcasing groundbreaking advancements in lung cancer and our ongoing partnerships with some of the brightest minds in the industry.
Â
This event will feature a keynote presentation and a panel discussion with J&J oncology leaders and guests, followed by an interactive Q&A and networking reception.
Â
We look forward to bringing together leaders across research, innovation, and investment for an evening of knowledge sharing and collaboration.
If you are developing bold, differentiated, and potentially transformative therapeutic approaches in the below areas we would like to hear from you:
- Lung cancer (small cell and non-small cell, including squamous and adenocarcinoma)
- Head and neck cancers
- Bladder, prostate, or hematologic malignancies
- Interventional oncology solutions, including controlled release, localized depot drug delivery, and integrated platforms for delivering, monitoring, and confirming intra-tumoral therapies
Selected applicants will be invited to present their projects directly to Johnson & Johnson’s Oncology Leaders.
- Apply for the 1:1 meeting application form and upload non-confidential information by June 10, 2026
- Selected companies will be notified on June 19, 2026
- Meetings will be held in-person in Seattle, Washington on July 6, 2026
If you have any questions, please contact Merritt Carver at mcarver3@its.jnj.com.
Dr. Bauml is the Lung/H&N Cancer Disease Area Stronghold Leader at Johnson & Johnson Innovative Medicine. As the Lung/H&N Cancer DAS leader, Dr. Bauml is responsible forend-to-end Lung/H&N Cancer Development including mature assets (Rybrevant and Lazertinib) as well as identifying new assets in early development and/or partnerships.
He received his undergraduate from Tufts University, Boston and completed his residency and earned his MD at the Icahn School of Medicine at Mt. Sinai. He completed his fellowship at the University of Pennsylvania. After his fellowship, Dr. Bauml was a faculty member at the University of Pennsylvania for 8 years, treating patients with lung and H&N cancers.
Dozie leads Oncology External Innovation activities for Johnson & Johnson in West North America, driving strategic partnerships, technical due diligences, and championing equity investments to advance the Oncology portfolio. He has spearheaded collaborations and numerous evaluations, shaping transformational research and development initiatives.
Previously, Dozie headed Johnson & Johnson Innovation JLABS in Canada, supporting over 100 life science start-ups at one of the country’s largest life science incubators. His leadership spans internal and external ecosystems, complemented by advisory roles with the University of Michigan’s MTRAC program and Creative Destruction Labs.
He serves on the boards of the Society of Toxicology and other not for profit life science organizations and has advised government bodies in Canada and Nigeria on Science and Innovation. As a scientist, Dozie has also contributed to the development of multiple Oncology products, including Tecvayli, Talvey, Rybrevant and others.
He has authored 10 book chapters, 24 peer-reviewed articles and numerous meeting abstracts. Dozie holds a dual Ph.D. in Comparative Medicine and Integrative Toxicological Sciences from Michigan State University, where he also completed a Veterinary Pathology residency. He earned his D.V.M. from the University of Nigeria and is board-certified in both Toxicology and Veterinary Pathology.
This program is from Johnson & Johnson and represents a selection of activities from across our Innovation Centers, JLABS and JJDC. The information in this program is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson and its affiliates or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, Johnson & Johnson do not endorse these third parties or any of the information provided in this program. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson. Johnson & Johnson is not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this program, Johnson & Johnson does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this program and is not responsible for any use by or alterations of this information by you. Johnson & Johnson hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this program.
